Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$23.35
▼ $0.53 (-2.2%)
Market data updated: 09/19 04:02 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$1.14B
Day Range
$23.31 - $24.26
52-Week Range
$19.16 - $48.25
Beta
—
Next Earnings
04.11.2026
Support
$22.83
Resistance
$30.14
AORT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-43.5% (1Y)
Strengths: 11/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 165.6%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$2.84 vs. price $23.35 (-112.2%)
Fair Value
Signal tension
Growth scores strong (65/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
48
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
65
Quality
63
Value
33
Momentum
23
Risk
46
Sentiment
86
Fundamental
54
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Artivion, Inc.** has centered on its stock performance, valuation debates, and market sentiment. Analysts discuss whether the company’s shares are undervalued or overpriced, with mixed views on cash flow versus sales metrics. The **AMDS launch narrative** remains a key focus, alongside insider selling and analyst upgrades, including a price target hike to **$40**. Earnings call insights and speculative discussions about long-term potential also feature prominently.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Artivion, Inc.. News trend score: 86. Reason: 10 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
42
Psychology
55
Fundamentals
54
Technical
23
Valuation
33
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
+10%
Market Narrative
47
Fundamental Reality
42
Narrative Gap
+5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant anchoring behavior (score 46) suggests traders are fixated on the 2.7% proximity to support, likely using it as a reference point for entry/exit decisions. The narrative-reality gap (3 points) hints at a mild disconnect between market perception and fundamentals, but the muted FOMO (8) and absence of panic (24) indicate cautious, non-emotional positioning. The key question is whether traders will hold near support or break away—momentum remains negative (-9.8% ROC), but sentiment (80) remains resilient. Overconfidence and herding are absent, reinforcing a disciplined, anchor-bound approach.
Updated: 09/09/2026, 01:16 PM
What could change this?
👥 What the crowd believes
"Canaccord Genuity analyst William Plovanic maintains Artivion (AORT) with a Buy and raises the price target from $39 to $40"
"Product Momentum and Pipeline Expansion Support Positive Outlook"
"Artivion Insider Sold Shares Worth $2,026,850"
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 100/100
🔴 Weakest match
Jesse Livermore — 18/100
🗣️ Why do they disagree?
The stark divide in verdicts for AORT reflects deep methodological contrasts: bullish momentum traders like Samuel Armstrong Nelson and Walter Bagehot see it as a cyclically favorable or liquidity-resilient play, scoring near the top (96 and 93) due to oversold conditions or resilience to credit stress. Meanwhile, growth-focused investors like Peter Lynch (83) and Charles Mackay (82) cautiously endorse it as a potential underappreciated opportunity, though without the same conviction as the cyclical or liquidity-driven approaches. On the other end, value purists like Benjamin Graham (41) and Morgan Housel (23) dismiss it outright—Graham’s defensive criteria fail, while Housel flags excessive volatility that would deter patient long-term holders. Even the efficient-market camp (40) questions its outperformance potential, while Livermore’s near-zero score (13) aligns with his contrarian trend-following rule, suggesting the stock’s trajectory clashes with his core strategy.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 93
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 85
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 78
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 70
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 64
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 59
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 48
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 42
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 36
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 23
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 18
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
64.4%
Operating Margin
7.6%
Net Margin
2.2%
EBITDA Margin
12.7%
ROE
2.2%
ROA
1.1%
ROIC
—
EPS
$0.22
Cash
$64.91M
Total Debt
$215.11M
Current Ratio
3.53
Debt/Equity
0.48
How is Fair Value calculated? →
Current Price
$23.35
Estimated Fair Value (DCF)
-$2.84
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-112.2%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
12.1%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 12.1% | $940.12K | $862.50K |
| 2 | 9.7% | $1.03M | $867.76K |
| 3 | 7.3% | $1.11M | $854.04K |
| 4 | 4.9% | $1.16M | $821.82K |
| 5 | 2.5% | $1.19M | $772.81K |
Base FCF (last actual year)
$839.00K
Terminal Value
$18.75M
Present Value of Terminal Value
$12.19M
Enterprise Value
$16.37M
Net Debt
$150.21M
Equity Value
$-133.84M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$9.50
Tangible Book Value per Share (Tangible NAV)
$1.49
Sentiment based on basic keywords (not AI) — 10 positive, 6 neutral, 4 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 11.9.2026
Yahoo · 8.9.2026
StockStory · 8.9.2026
Yahoo · 4.9.2026
StockStory · 4.9.2026
Simply Wall St. · 27.8.2026
Simply Wall St. · 27.8.2026
StockStory · 25.8.2026
MT Newswires · 20.8.2026
StockStory · 19.8.2026
Benzinga · 18.8.2026
StockStory · 15.8.2026
Motley Fool · 14.8.2026
StockStory · 11.8.2026
SeekingAlpha · 9.8.2026
MarketBeat · 7.8.2026
Insider Monkey · 7.8.2026
MT Newswires · 7.8.2026
GuruFocus.com · 7.8.2026
Artivion, Inc. (AORT) currently has a StockIQ AI score of 48/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AORT currently scores 48/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, AORT's estimated fair value is -$2.84, which is 112.2% below the current price of $23.35. This is one valuation model among several signals in the fair-value category, not a price target.
AORT's technical score is 23/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 165.6%; Net income growth: 173.1%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Estimated fair value: -$2.84 vs. price $23.35 (-112.2%); ATR: 4.6% of price; Calmar: 0.27 (3y annualized return 15.6% / max drawdown 57.8%).
StockIQ has no recorded dividend payment history for AORT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| GREEN ANDREW M | Open Market Sale | 3.9.2026 | 1,493 | -1,493 | $26.02 |
| GREEN ANDREW M | Open Market Sale | 2.9.2026 | 6,510 | -6,510 | $27.27 |
| Mackin James P | Open Market Sale | 19.8.2026 | 70,000 | -70,000 | $28.96 |
| Berry Lance A | Open Market Sale | 14.8.2026 | 715 | -715 | $28.55 |
| GREEN ANDREW M | Open Market Sale | 14.8.2026 | 616 | -616 | $28.55 |
| Holloway Jean F | Open Market Sale | 12.8.2026 | 977 | -977 | $28.49 |
| Holloway Jean F | Open Market Sale | 12.8.2026 | 184,118 | -977 | $28.49 |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 14,001 | +14,001 | $18.44 |
| GREEN ANDREW M | Open Market Sale | 11.6.2026 | 14,001 | -14,001 | $20.71 |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 14,001 | -14,001 | — |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 30,000 | +30,000 | $11.03 |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 30,000 | -30,000 | — |
| GREEN ANDREW M | Open Market Sale | 11.6.2026 | 30,000 | -30,000 | $20.69 |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 74,260 | +14,001 | $18.44 |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 90,259 | +30,000 | $11.03 |
| GREEN ANDREW M | Open Market Sale | 11.6.2026 | 60,259 | -30,000 | $20.69 |
| GREEN ANDREW M | Exercise of Derivative Securities | 11.6.2026 | 0 | -30,000 | — |
| SEMEDO ANTHONY B. | Other Transaction | 2.6.2026 | 6,325 | -6,325 | — |
| SEMEDO ANTHONY B. | Other Transaction | 2.6.2026 | 6,325 | +6,325 | — |
| SEMEDO ANTHONY B. | Other Transaction | 2.6.2026 | 40,635 | -6,325 | — |
| SEMEDO ANTHONY B. | Other Transaction | 2.6.2026 | 6,325 | +6,325 | — |
| Bullock James | Grant/Award from Employer | 18.5.2026 | 7,576 | +7,576 | — |
| Hoff Elizabeth A | Grant/Award from Employer | 18.5.2026 | 7,576 | +7,576 | — |
| Salveson Jon W | Grant/Award from Employer | 18.5.2026 | 7,576 | +7,576 | — |
| ACKERMAN THOMAS F | Grant/Award from Employer | 18.5.2026 | 7,576 | +7,576 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,927,038 shares short as of 2026-08-31 · vs. 2,705,501 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.3% of trading volume this week was short selling, vs. 64.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology